1
Michael G Schlossmacher, Dennis J Selkoe: Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, June 16, 1998: US05766846 (126 worldwide citation)

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


2
Dale B Schenk, Michael G Schlossmacher, Dennis J Selkoe, Peter A Seubert, Carmen Vigo Pelfrey: Methods and compositions for the detection of soluble .beta.-amyloid peptide. Athena Neurosciences, Eli Lilly and Company, Brigham and Women s Hospital, Townsend and Townsend and Crew, November 17, 1998: US05837672 (81 worldwide citation)

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


3

4
Dennis J Selkoe: Diagnostic method for Alzheimers disease: examination of non-neural tissue. Brigham and Women s Hospital, Lyon & Lyon, November 16, 1993: US05262332 (62 worldwide citation)

This invention provides a method as well as a kit for diagnosing Alzheimer's disease. The method comprises the steps of obtaining a non-neural tissue biopsy sample, contacting at least a portion of the sample with a quantity of antibodies capable of identifying .beta.AP, a .beta.-amyloid precursor p ...


5
Martin Citron, Dennis J Selkoe, Peter A Seubert, Dale Schenk: Screening compounds for the ability to alter the production of amyloid-&bgr; peptide. Brigham and Women&apos s Hospital, Athena Neurosciences, Townsend and Townsend and Crew, August 26, 2003: US06610493 (43 worldwide citation)

This invention provides methods of screening compounds for their ability to alter the production of A&bgr;(x≧41) alone or in combination with A&bgr;(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of A&bgr;(x≦40) and A&bgr;(x≧41) produced b ...


6
Martin Citron, Dennis J Selkoe, Peter A Seubert, Dale B Schenk: Methods for determining whether a compound alters the amount of at least one αβ (X-41) peptide and the amount of either total αβ or at least one αβ (X-40) peptide produced by a non-human mammal. Elan Pharmaceuticals, Brigham and Women s Hospital, Alston and Bird, August 9, 2011: US07993627

This invention provides methods of screening compounds for their ability to alter the production of Aβ(x≧41) alone or in combination with Aβ(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of Aβ(x≦40) and Aβ(x≧41) produced by the cells, and comparing t ...


7
Michael S Wolfe, Dennis J Selkoe: (Hydroxyethyl)ureas as inhibitors of alzheimer's &bgr;-amyloid production. The Brigham and Women&apos s Hospital, Wolf Greenfield and Sacks P C, February 24, 2004: US06696488

Novel (hydroxyethyl)ureas are described. These compounds are effective inhibitors of certain aspartyl proteases, notably secretases involved in the enzymatic cleavage of amyloid precursor protein (APP) to yield amyloid-&bgr; peptide. Methods are provided for administering the novel compounds to trea ...


8
Michael S Wolfe, Dennis J Selkoe: Hydroxyethyl ureas as inhibitors of alzheimers beta-amyloid production. Wolf Greenfield & Sacks PC, Federal Reserve Plaza, August 15, 2002: US20020111365-A1

Novel (hydroxyethyl)ureas are described. These compounds are effective inhibitors of certain aspartyl proteases, notably secretases involved in the enzymatic cleavage of amyloid precursor protein (APP) to yield amyloid- peptide. Methods are provided for administering the novel compounds to treat -am ...


9
Martin Citron, Dennis J Selkoe, Peter A Seubert, Dale B Schenk: Screening compounds for the ability to alter the production of amyloid-beta peptide (x-41). Athena Neurosciences a Delaware corporation, Townsend And Townsend And Crew, August 7, 2003: US20030148392-A1

This invention provides methods of screening compounds for their ability to alter the production of A(x41) alone or in combination with A(x40). The methods involve administering compounds to cells, specifically measuring the amounts of A(x40) and A(x41) produced by the cells, and comparing these amo ...


10
Alon Monsonego, Howard Weiner, Dennis J Selkoe: Amyloid beta-peptide and methods of use. Fish & Richardson PC, June 9, 2005: US20050123553-A1

Novel compositions containing an amyloid-β peptide (Aβ) and methods of using these compositions for treating and preventing Aβ protein related (e.g., an amyloid fibril) disorders such as Alzheimer's disease are described herein. Also described herein are methods for identifying a vaccine, and method ...